Blood Plasma Derivatives Market Growth 2028 Projections: 9.4% CAGR to Reach $51Bn by 2028 Led by Immunoglobulins Segment | The Insight Partners

The blood plasma derivatives market growth is fuelled by the increasing prevalence of blood disorders, increasing usage of immunoglobulin G in multiple treatments, and rise in the geriatric population.

New York, March 22, 2023 (GLOBE NEWSWIRE) -- According to The Insight Partners, “Blood Plasma Derivatives Market Size, Share, Growth, Trends and Global Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (Albumin, Factor VIII, Factor IX, Immunoglobulin, Hyperimmune Globulin, and Others), Application (Hemophilia, Hypogammaglobulinemia, Immunodeficiency Diseases, von Willebrand’s Diseases, and Others), and End User (Hospitals, Clinics, and Others)”, the global blood plasma derivatives market size to reach USD 51.11 billion by 2028 with CAGR of 9.4% from 2022 to 2028, it was valued at USD 29.88 billion in 2022.

Download PDF Brochure at

Global Blood Plasma Derivatives Market - Study Scope:

Market Size Value in USD 29.88 Billion in 2022
Market Size Value by USD 51.11 Billion by 2028
Growth rate CAGR of 9.4% from 2022 to 2028
Forecast Period 2022-2028
Base Year 2022
No. of Pages 209
No. of Tables 111
No. of Charts & Figures 80
Historical data available Yes
Segments covered Type, Application, and End User

Blood Plasma Derivatives Market Analysis: Competitive Landscape and Key Developments

Grifols SA, SK Plasma Co Ltd, Octapharma AG, Monobind Inc., Intas Pharmaceuticals Ltd, Fusion Health Care Pvt Ltd, Takeda Pharmaceutical Co Ltd, CSL Behring LLC, LFB SA, and Kedrion SpA are a few key companies operating in the blood plasma derivatives market. The market leaders focus on new product launches, expansion and diversification, and acquisition strategies, which allow them to access prevailing business opportunities.

In July 2022, Takeda announced that ADVANCE-1 met its primary endpoint. ADVANCE-1 is a randomized, placebo-controlled, double-blind Phase 3 clinical trial evaluating HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] for the maintenance treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Data show that HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] reduced relapse rate versus placebo in CIDP patients when used as a maintenance therapy.

In February 2022, Grifols announced a collaboration with Endpoint Health, Inc., a precision-medicine therapeutics company dedicated to addressing urgent needs in immune-driven critical care. Through this collaboration, companies aim to develop and commercialize an Antithrombin III (AT-III) therapy to treat Sepsis. As part of the agreement, Grifols will contribute its industry-leading expertise in plasma-protein therapies and be the exclusive supplier of AT-III, a plasma protein that treats patients suffering from blood clotting issues.

In June 2021, Kedrion Biopharma and Kamada Ltd. announced that the U.S. Food and Drug Administration (FDA) had approved a label update for KEDRAB [Rabies Immune Globulin (Human)], establishing the product’s safety and effectiveness in children.

Inquiry Before Purchase:

Impact of COVID-19 Pandemic of Global Blood Plasma Derivatives Market Growth:

The rising number of COVID-19 cases propelled the demand for blood plasma derivatives. Patients suffering from underlying immunodeficient disorders, including hypogammaglobulinemia and specific antibody deficiency (SDA), were at a greater risk of novel coronavirus infection and more likely to have higher morbidity and mortality. However, only essential procedures were allowed in hospitals during the lockdown, which delayed or canceled the immunoglobulin-based therapies. Additionally, various studies published in PubMed and NCBI by researchers show that intravenous immunoglobulin has demonstrated clinical efficacy in critically ill COVID-19 patients in reducing the rate of mortality. Post-COVID-19 pandemic, there has been a significant increase in the demand for plasma derivatives owing to the surge in immunoglobulin replacement therapies. Thus, the COVID-19 pandemic positively impacted the blood plasma derivatives market.

Increasing Prevalence of Blood Disorders Bolster the Global Blood Plasma Derivatives Market Growth:

According to the National Organizations of Rare Disorders, hemophilia A is a common X-linked recessive disorder and the second most common inherited clotting factor deficiency after von Willebrand disease. According to the World Federation of Hemophilia (WFH) Annual Global Survey 2021, around 256,840 people across the world were affected by hemophilia in 2021. As per the WFH, in 2021, ~98,293 individuals globally had von Willebrand disease. Research published in NLM in 2020 stated that 80 million people in European Union suffer from blood disorders, ranging from cancer to bleeding disorders. According to National Organization for Rare Disorders, in 2022, immune thrombocytopenia (ITP), an autoimmune bleeding disorder, affects ~66 adults per 1 million in the US. Furthermore, the World Economic Forum reported in 2020 that more than 10% of the global population is affected by a rare disease. Since, plasma is a liquid portion of blood containing WBC and platelets. Blood plasma derivatives play a major role in treating many rare diseases. Thus, the increasing prevalence of blood disorders across the world promotes the blood plasma derivatives market growth.

Speak to Research Expert:

Blood Plasma Derivatives Market - Growth Dynamics:

The increasing prevalence of blood disorders and rising geriatric population fuel the blood plasma derivatives market growth. Additionally, the incorporation of platelet-rich plasma in regenerative medicine is expected to provide lucrative opportunities to the market during the forecast period.

The US holds a significant blood plasma derivatives market share. The prevalence of severe diseases, including hemophilia and immune deficiency disorders, is driving market growth. According to the Centers for Disease Control and Prevention (CDC) data, Hemophilia A affects 1 in 5,000 male births. About 400 babies are born with hemophilia A each year. The exact number of people affected by hemophilia in the US is unknown. Based on a recent study that used data collected on patients receiving care in federally funded hemophilia treatment centers during 2012–2018, as many as 33,000 males in the US suffer from the disorder. Furthermore, as per World Health Organization (WHO), out of 250,000 individuals diagnosed with primary immune deficiencies (PID) in the US in 2017, roughly 125,000 get month-to-month mixtures of immunoglobulins. It is assessed that more than 300,000 patients get monthly-to-month immunoglobulins implantations for PID. The rising prevalence of chronic conditions and increasing demand for immunoglobulin drive the growth of the blood plasma derivatives market.

Buy Premium Copy of Blood Plasma Derivatives Market Growth Report (2022-2028) at:

Browse Adjoining Reports:

Blood Plasma Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Components(Albumin, Coagulation Factors, Immunoglobin, Hyperimmune and Other Plasma Fractionation Products); Application(Oncology, Rheumatology, Neurology, Transplant, Immunology, Pulmonology and Hematology); End User(Research laboratories, hospitals and clinics and academic institutions.)

Blood Plasma Thawer Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (Below 4 Bags, 4-8 Bags, Above 8 Bags); End-users (Blood Bank Centers, Hospitals, Clinical and Research Laboratories, Other) and Geography

Albumin Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product (Human Serum Albumin, Bovine Serum Albumin and Recombinant Albumin); Application(Therapeutics, Drug Formulation & Vaccines, Component of media and Other Applications)

Immunoglobulin Market Forecast to 2028 - Covid-19 Impact and Global Analysis - By Mode of Delivery (Subcutaneous and Intravenous); Application (Hypogammaglobulinemia, Immunodeficiency Disease, Multifocal Motor Neuropathy, Guillain-Barre Syndrome, Myasthenia Gravis, Chronic Inflammatory Demyelinating Polyneuropathy, and Others); Product (IgA, IgD, IgG, IgE, and IgM)

Gamma Globulin Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type (Injection, Lyophilized powder); Application (Neurological and neuromuscular disease treatment, Central nervous system disease treatment, Peripheral nerves disease treatment, Neuromuscular junction and muscles disease treatment); and Geography

Hemophilia Treatment Market to 2027 - Global Analysis and Forecasts by Product (Plasma Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytic Agents); Disease (Hemophilia A, Hemophilia B, Hemophilia C); Treatment Type (On-demand, Prophylaxis); Therapy (Replacement Therapy, ITI Therapy, Gene Therapy, Antibody Therapy); End User (Hospitals, Clinics, Ambulatory Surgical Centres, Others), and Geography

Primary Immunodeficiency Diseases Treatment Market Forecast to 2028 - COVID-19 Impact and Global Analysis by Disease (Innate Immune Disorders, Cellular Immunodeficiency, Antibody Deficiency); Test (Prenatal Testing, Blood Test); Treatment (Antibiotic Therapy, Stem cell and Gene Therapy, Immunoglobulin Replacement Therapy, Others); Test (Prenatal Testing, Blood Test)

Recombinant factor VIII Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (200IU, 250IU); Application (Hospital, Pharmacy) and Geography

About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:
If you have any queries about this report or if you would like further information, please contact us:

Contact Person: Sameer Joshi
Press Release: